<SEC-DOCUMENT>0001144204-13-062355.txt : 20131115
<SEC-HEADER>0001144204-13-062355.hdr.sgml : 20131115
<ACCEPTANCE-DATETIME>20131115140322
ACCESSION NUMBER:		0001144204-13-062355
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20131115
DATE AS OF CHANGE:		20131115
GROUP MEMBERS:		KI YONG CHOI & LAURA H. CHOI

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SERVICES, NEC [8900]
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-80299
		FILM NUMBER:		131223454

	BUSINESS ADDRESS:	
		STREET 1:		700 BROOKER CREEK BLVD
		STREET 2:		SUITE 1800
		CITY:			OLDSMAR
		STATE:			FL
		ZIP:			34677
		BUSINESS PHONE:		813-749-2104

	MAIL ADDRESS:	
		STREET 1:		700 BROOKER CREEK BLVD
		STREET 2:		SUITE 1800
		CITY:			OLDSMAR
		STATE:			FL
		ZIP:			34677

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Choi Ki Yong
		CENTRAL INDEX KEY:			0001407536

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	MAIL ADDRESS:	
		STREET 1:		1255 POST STREET, SUITE 915
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94109
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>v360687_sc13da.htm
<DESCRIPTION>SC 13D/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 13D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Under the Securities Exchange Act of
1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Amendment No. 8)*</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">CRYO CELL INTERNATIONAL, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Name of Issuer)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">(Title of Securities)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center"><FONT STYLE="font-size: 10pt">228895108</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">(CUSIP Number)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center"><FONT STYLE="font-size: 10pt">Kevin Friedmann, Esq.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Richardson &amp; Patel LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">750 Third Avenue, 9<SUP>th</SUP> Floor</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">New York, New York 10017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">(212) 561-5559</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Name, Address and Telephone Number of Person
    Authorized to</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Receive Notices and Communications)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">November 13, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Date of Event Which Requires Filing of This
    Statement)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule
13d-1(f) or Rule 13d-1(g), check the following box.[ ]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*The remainder of this cover page shall be filled out for a
reporting person&rsquo;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.<BR>
<BR>
The information required on the remainder of this cover page shall not be deemed to be &ldquo;filed&rdquo; for the purpose of
Section 18 of the Securities Exchange Act of 1934 (&ldquo;Act&rdquo;) or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="border-top: black 1pt solid">CUSIP No.&nbsp; 2228895108&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-top: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-top: black 1pt solid">1.</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid">Names of Reporting Persons</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">IRS Identification Nos. of Above Persons
        (Entities Only)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid">Ki Yong Choi&nbsp;</TD></TR>
<TR>
    <TD>2.</TD>
    <TD COLSPAN="2">Check the Appropriate Box if a Member of a Group (See Instructions)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>(a)&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>(b)&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings 2">&pound;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>3.</TD>
    <TD COLSPAN="2">SEC Use Only</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>4.</TD>
    <TD COLSPAN="2">Source of Funds (See Instructions)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">PF&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>5.</TD>
    <TD COLSPAN="2">Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)</TD>
    <TD STYLE="font-family: Wingdings 2">&pound;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>6.</TD>
    <TD COLSPAN="2">Citizenship or Place of Organization</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">United States&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 4%">7.</TD>
    <TD STYLE="width: 74%"> Sole Voting Power </TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">NUMBER OF</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">SHARES</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">1,945,596</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">BENEFICIALLY</TD>
    <TD>8.</TD>
    <TD>Shared Voting Power</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">OWNED BY</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">EACH</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">233,472 (1)&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">REPORTING</TD>
    <TD>9.</TD>
    <TD>SOLE DISPOSITIVE POWER</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">PERSON</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">WITH</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">1,945,596&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>10.</TD>
    <TD>Shared Dispositive Power</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">233,472 (1)&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>11.</TD>
    <TD COLSPAN="2"> Aggregate Amount Beneficially Owned by Each Reporting Person&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">2,179,068</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>12.</TD>
    <TD COLSPAN="2">Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="font-family: Wingdings 2">&pound;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>13.</TD>
    <TD COLSPAN="2">Percent of Class Represented by Amount in Row (11)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">20.2% (2)&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>14.</TD>
    <TD COLSPAN="2">Type of Reporting Person (See Instructions)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">IN&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">By virtue of being a co-trustee of the Ki Yong Choi and Laura H. Choi, as trustees UAD 7/27/01 FBO Choi
Family Living Trust (the &ldquo;Trust&rdquo;), Mr. Choi shares voting and dispositive power over the 233,472 shares of common stock
held by the Trust.</P>


</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">Based upon 10,761,325 shares of common stock outstanding as of October 2, 2013 as reported in the Company&rsquo;s
Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on October 15, 2013.</P>


</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="border-top: black 1pt solid">CUSIP No.&nbsp; 2228895108&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-top: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-top: black 1pt solid">1.</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid">Names of Reporting Persons</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">IRS Identification Nos. of Above Persons
        (Entities Only)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><P STYLE="margin: 0pt 0">Ki Yong Choi and Laura H. Choi, as trustees UAD 7/27/01 FBO Choi Family Living Trust</P>


</TD></TR>
<TR>
    <TD>2.</TD>
    <TD COLSPAN="2">Check the Appropriate Box if a Member of a Group (See Instructions)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>(a) <FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>(b)&nbsp;<FONT STYLE="font-family: Wingdings 2">&pound;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>3.</TD>
    <TD COLSPAN="2">SEC Use Only</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>4.</TD>
    <TD COLSPAN="2">Source of Funds (See Instructions)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid"> PF</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>5.</TD>
    <TD COLSPAN="2">Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)</TD>
    <TD STYLE="font-family: Wingdings 2">&pound;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>6.</TD>
    <TD COLSPAN="2">Citizenship or Place of Organization</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">California</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 4%">7.</TD>
    <TD STYLE="width: 74%"> Sole Voting Power </TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">NUMBER OF</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">SHARES</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">0&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">BENEFICIALLY</TD>
    <TD>8.</TD>
    <TD>Shared Voting Power</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">OWNED BY</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">EACH</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">233,472 (1)&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">REPORTING</TD>
    <TD>9.</TD>
    <TD>SOLE DISPOSITIVE POWER</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">PERSON</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">WITH</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">0&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>10.</TD>
    <TD>Shared Dispositive Power</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">233,472 (1)&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>11.</TD>
    <TD COLSPAN="2"> Aggregate Amount Beneficially Owned by Each Reporting Person&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> 233,472 (1)&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>12.</TD>
    <TD COLSPAN="2">Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="font-family: Wingdings 2">&pound;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>13.</TD>
    <TD COLSPAN="2">Percent of Class Represented by Amount in Row (11)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">.02% (2)</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>14.</TD>
    <TD COLSPAN="2">Type of Reporting Person (See Instructions)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> OO</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">By virtue of being a co-trustee of the Ki Yong Choi and Laura H. Choi, as trustees UAD 7/27/01 FBO Choi
Family Living Trust (the &ldquo;Trust&rdquo;), Mr. Choi shares voting and dispositive power over the 233,472 shares of common stock
held by the Trust.</P>


</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Based upon 10,761,325 shares of common stock outstanding as of October 2, 2013 as reported in the Company&rsquo;s
Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on October 15, 2013.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">Item 1.</TD><TD STYLE="text-align: justify">Security and Issuer</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Amendment No. 8 to Schedule
13D (&ldquo;Amendment No. 8&rdquo;) by Ki Yong Choi and Ki Yong Choi and Laura H. Choi, as trustees UAD 7/27/01 FBO Choi
Family Living Trust (the &ldquo;Trust&rdquo; and collectively, the &ldquo;Reporting Persons&rdquo;) amends and supplements
the statement on Schedule 13D originally filed on July 26, 2007 by Mr. Choi, as subsequently amended, relating to the common
stock, par value $0.01 per share (the &ldquo;Common Stock&rdquo;) of Cryo-Cell International, Inc., a Delaware
corporation (the &ldquo;Issuer&rdquo;), with its principal executive offices located at 700 Brooker Creek Boulevard, Suite
1800, Oldsmar, Florida 34677. Information given in response to each item shall be deemed incorporated by reference in all
other items, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">Item 4.</TD><TD STYLE="text-align: justify">Purpose of Transaction</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Item 4 of Schedule 13D is hereby amended
to include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 13, 2013 Ki-Yong Choi, derivatively
on behalf of the Issuer, filed a complaint (the &ldquo;Complaint&rdquo;) in the Circuit Court for the Thirteenth Judicial District
in and for Hillsborough County, Florida against David I. Portnoy, Mark L. Portnoy (collectively, David I. Portnoy and Mark L. Portnoy
are sometimes referred to herein as the &ldquo;Portnoy Defendants&rdquo;), Anthony Atala, Harold D. Berger, George Gaines and Jonathan
H. Wheeler (collectively, the &ldquo;Defendants&rdquo;) and the Issuer, as a nominal defendant. The Complaint alleges that the
Defendants (i) breached their duty to the Issuer&rsquo;s stockholders by engaging in activities (the &ldquo;Transactions&rdquo;)
that diverted corporate assets to themselves and/or other insiders in a manner to benefit the Portnoy Defendants and their friends
and to ensure their entrenchment with the Issuer; (ii) engaged in systematic misconduct for the purpose of maintaining and entrenching
themselves in their positions of power, thereby abusing their ability to control and to influence the Issuer; (iii) gave away substantial
sums of money causing waste to valuable assets belonging to the Issuer; and, as a result of the foregoing, (iv) the Defendants
were unjustly enriched at the expense of the Issuer. The Complaint requests that the Court rescind the Transactions; assess damages
against the Defendants in an amount to be proven at trial; remove from management any Defendant found to have breached his fiduciary
duty to the Issuer; require the return of all compensation paid by the Issuer to each Defendant found to have breached a fiduciary
duty to the Issuer to the maximum extent permitted by law; award attorney&rsquo;s fees to the extent permissible; award costs of
the legal action; award pre-judgment and post-judgment interest to the extent permissible; and award such other and further relief
as the Court may deem just, equitable or proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Depending on various factors, including the
Issuer&rsquo;s financial position, results of operations and strategic direction, the outcome of discussions with other stockholders
and the Issuer, actions taken by the Issuer, and the trading price levels of the Common Stock of the Issuer, the Reporting Persons
may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without
limitation, purchasing additional shares of Common Stock of the Issuer or selling some or all of their shares of Common Stock of
the Issuer, and/or otherwise changing their intentions with respect to any and all matters referred to in paragraphs (a) through
(j) of Item 4 of Schedule 13D.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>Item 5.</B></TD><TD STYLE="text-align: justify"><B>Interest in Securities of the Issuer</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The aggregate percentage of Common Stock
reported owned by the Reporting Persons is based upon 10,761,325 shares of Common Stock outstanding, which is the total number
of shares of Common Stock outstanding as reported in the Issuer&rsquo;s Quarterly Report on Form 10-Q for the fiscal quarter ended
September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the close of business on November 13,
2013, Ki-Yong Choi beneficially owned 2,179,068 shares of the Common Stock, constituting approximately 20.2% of the Common Stock
outstanding. As the co-trustee of the Ki Yong Choi and Laura H. Choi, as trustees UAD 7/27/01 FBO Choi Family Living Trust (the
&ldquo;Trust&rdquo;), Mr. Choi shares voting and dispositive power over the 233,472 shares of common stock held by the Trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>Item 7.</B></TD><TD STYLE="text-align: justify"><B>Material to Be Filed as Exhibits</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; text-indent: 0.5in">Item 7 is hereby amended to include the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">99.1.&#9;Complaint in the Circuit Court for the Thirteenth
Judicial District in and for Hillsborough County, Florida against David I. Portnoy, Mark L. Portnoy (collectively, David I. Portnoy
and Mark L. Portnoy are sometimes referred to herein as the &ldquo;Portnoy Defendants&rdquo;), Anthony Atala, Harold D. Berger,
George Gaines and Jonathan H. Wheeler (collectively, the &ldquo;Defendants&rdquo;) and the Issuer, as a nominal defendant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">99.2.&#9;Joint Filing Agreement between the Reporting Persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 14, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD STYLE="width: 3%">&nbsp;</TD>    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Ki Yong Choi</TD>    <TD STYLE="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>Ki Yong Choi</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>&nbsp;</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>Ki Yong Choi and Laura Choi, as Trustees UAD 7/27/01</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>FBO Choi Family Living Trust</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>&nbsp;</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>&nbsp;</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>&nbsp;</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>By:</TD>    <TD STYLE="border-bottom: Black 1pt solid">/s/ Ki Yong Choi, Trustee</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>Ki Yong Choi, Trustee</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>&nbsp;</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>&nbsp;</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>&nbsp;</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>By:</TD>    <TD STYLE="border-bottom: Black 1pt solid">/s/ Laura H. Choi</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>    <TD>&nbsp;</TD>    <TD>Laura H. Choi, Trustee</TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v360687_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IN THE CIRCUIT COURT FOR THE THIRTEENTH
JUDICIAL DISTRICT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IN AND FOR HILLSBOROUGH COUNTY, FLORIDA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">COMPLEX BUSINESS LITIGATION DIVISION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KI YONG CHOI, derivatively on behalf of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CRYO CELL INTERNATIONAL, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Plaintiff,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">vs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DAVID I. PORTNOY, MARK L. PORTNOY,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ANTHONY ATALA, HAROLD D. BERGER. &#9;CASE
NO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GEORGE GAINES, JONATHAN H. WHEELER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Defendants,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CRYO CELL INTERNATIONAL, INC.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nominal Defendant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_________________________________________/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>VERFIED SHAREHOLDER DERIVATIVE COMPLAINT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">COMES NOW, plaintiff Ki Yong Choi (&ldquo;Plaintiff&rdquo; or
&ldquo;Choi&rdquo;), derivatively on behalf of Nominal Defendant Cryo Cell International, Inc. (&ldquo;Cryo Cell&rdquo; or the
&ldquo;Company&rdquo;), by and through counsel, and complains and states as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NATURE OF THE ACTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">1.&nbsp;&nbsp;This a shareholder derivative
action brought by Plaintiff against the Company&rsquo;s co-chief executive officers (&ldquo;CEOs&rdquo;) and directors, brothers
David I. Portnoy and Mark L. Portnoy, as well as current and former directors Anthony Atala, Harold D. Berger, George Gaines, and
Jonathan H. Wheeler (collectively, &ldquo;Individual Defendants&rdquo;). Since their election to the Company&rsquo;s board of directors
in late August 2011, and appointment as CEOs shortly thereafter, the Portnoys have consistently pursued their own personal enrichment
and entrenchment at the Company at the expense of shareholder interests. By this action, Plaintiff seeks redress from the Individual
Defendants&rsquo; self-dealing and suppression of shareholder rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">2.&nbsp;&nbsp;Though they sought election
to the Company&rsquo;s board of directors (the &ldquo;Board&rdquo;) on the platform that the Company&rsquo;s executive compensation
was too high, the Portnoys immediately installed themselves as co-CEOs, increasing overall CEO costs. They then lavished hundreds
of thousands of shares of unwarranted stock options upon themselves, causing these stock options to vest on an accelerated basis
upon any nomination of directors to run against them. Thus, the Portnoys punished the Company and shareholders for even the <I>possibility</I>
that new directors could be elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">3.&nbsp;&nbsp;The Portnoys have also paid
themselves hundreds of thousands of dollars to which they are not legally entitled. In late 2011, the Portnoys awarded themselves
fees and costs they claim were incurred in a failed attempt to get seats on the Company&rsquo;s Board in 2007. They paid themselves
despite the Delaware Court of Chancery ruling several years prior that they were not entitled to these sums.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">4.&nbsp;&nbsp;In a similar vein, the Portnoys
appointed their friends and associates to positions of power throughout the Company. Specifically, they selected their friend and
convicted felon David Wayne Fish (&ldquo;Fish&rdquo;) to build the Company&rsquo;s sales force. Fish then immediately subjected
the Company to charges of sexual harassment. Likewise, Defendant M. Portnoy&rsquo;s on again, off again girlfriend, Iliana Belinc
(&ldquo;Belinc&rdquo;), was placed in charge of coordinating the Company&rsquo;s events. Finally, Defendant D. Portnoy selected
Oleg Mikunlisky (&ldquo;Mikunlisky&rdquo;), who he had previously employed at PartnerCommunity, Inc. (&ldquo;PC&rdquo;) and uTIPu,
Inc. (&ldquo;uTIPu&rdquo;) as the Company&rsquo;s Chief Information Officer (&ldquo;CIO&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">5.&nbsp;&nbsp;Defendants&rsquo; unfair favoritism
and entrenching actions should not be viewed in a vacuum. For example, in 2012, Glass Lewis, a recognized leading national proxy
advisory service, urged shareholders to vote against the Portnoys, describing their self-appointment as CEOs as a &ldquo;veiled
and substantial overreach of power&rdquo; at the Company and rejecting their &ldquo;preposterous&rdquo; justifications of self-appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">6.&nbsp;&nbsp;The Portnoys&rsquo; self-dealing
also continued during the Company&rsquo;s 2012 directorial election contest, where the Portnoys made numerous material misrepresentations
to shareholders, some of which they grudgingly admitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">7.&nbsp;&nbsp;Specifically, on July 5, 2012,
less than one week before the Company&rsquo;s 2012 Annual Meeting, the Portnoy Defendants made the following misrepresentation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">[The Portnoys] know exactly what it takes to reverse the
company&rsquo;s downward trend in revenue. Their plan is already showing positive results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This statement falsely indicates that Defendants had already
begun to turn Cryo Cell&rsquo;s results around. In fact, the Company&rsquo;s financial results in the Company&rsquo;s Form 10-Q
for the second quarter of 2012, which were first filed with the United States Securities and Exchange Commission (&ldquo;SEC&rdquo;)
July 16, 2012 after the close of the market (<I>i.e.</I> six days after the 2012 Annual Meeting), show otherwise. According to
the Form 10-Q, year-over-year revenues for that quarter had declined by more than 4%, from $4.6 million to $4.4 million. Even worse,
the Company&rsquo;s profitability for the quarter compared to the same quarter in the prior year had swung from a $177,000 profit
to a $3.2 million loss. In view of these facts, representing that the Company was showing &ldquo;positive results&rdquo; was highly
misleading and obviously calculated to deceive shareholders/voters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;In sum, the Portnoys&rsquo; two years in control
of the Company have been rife with self-dealing, currying favoritism on their criminal allies and defrauding shareholders to stay
in power. Because Defendants committed the wrongdoing alleged herein, they cannot reasonably be expected to initiate litigation
on the Company&rsquo;s behalf. Accordingly, Choi, the Company&rsquo;s largest single shareholder, proceeding derivatively on behalf
of the Company, is the proper party to prosecute this lawsuit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>JURISDICTION AND VENUE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in; text-align: justify">9.&nbsp;&nbsp;This
Court has jurisdiction over this matter under Article V of the Florida Constitution and Florida Statutes Section 26.012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">10.&nbsp;&nbsp;This Court has personal jurisdiction
over Nominal Defendant Cryo Cell and each Individual Defendant because: several defendants reside in the State of Florida; much
of the alleged wrongful conduct took place in the State of Florida; all of the Individual Defendants have transacted substantial
business in the State of Florida, where the Company is headquartered and they have served and/or continue to serve as officers
and directors; and the Individual Defendants have taken actions in furtherance of their wrongdoing in the State of Florida. Accordingly,
each defendant has purposefully availed himself of the benefit of doing business in the State of Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;Pursuant to Florida Statutes Section 47.011,
venue is proper in Hillsborough County Florida because Cryo Cell has its principal executive office in Oldsmar, Florida. Likewise,
substantial portions of the events at issue occurred, and substantial witnesses and evidence are located in this Hillsborough County
and Plaintiff&rsquo;s cause of action accrued in Hillsborough County.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;Plaintiff Ki Yong Choi is a currently a shareholder
of the Company and has been at all times relevant hereto. Choi is a citizen of the State of California and resides in Marin County.
At present, he beneficially owns approximately 2,179,068 common shares of Cryo Cell, or approximately 20.2% of shares outstanding
based on his shares owned as of the filing of this Complaint and reported shares outstanding as of October 15, 2013. Plaintiff
began acquiring shares of the Company more than eight years ago and has thus shown himself to be a long term holder of the Company&rsquo;s
stock, committed to its long term best interests and capable of fairly and adequately representing the Company and its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13. &nbsp;&nbsp;Nominal Defendant Cryo Cell International, Inc.
is, and, at all relevant times was, a corporation organized and existing under the laws of the State of Delaware. Its principal
executive offices are located in Oldsmar. According to its public filings, Cryo Cell engages in the business of cellular processing
and cryogenic storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use.
Since being under the Portnoys&rsquo; control in late 2011, Cryo Cell&rsquo;s financial performance has deteriorated. For example,
for Fiscal Year 2012, net losses increased by close to $4.3 million dollars, more than tripling to a greater than $6.3 million
annual loss. Millions of dollars of this loss is directly attributable to the Portnoys&rsquo; self-dealing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">14.&nbsp;&nbsp;Cryo Cell is named in this
Complaint as a Nominal Defendant pursuant to principles regarding the joinder of indispensable parties, which provide for Cryo
Cell&rsquo;s joinder as a nominal defendant in whose name the suit is brought derivatively. Based on Defendants&rsquo; response
to Plaintiff&rsquo;s pre-suit demand for the inspection of books and records, and in light of the Individual Defendants&rsquo;
control over Cryo Cell, Plaintiff believes that Cryo Cell&rsquo;s management are antagonistic to him and the relief he seeks herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;Defendant
David I. Portnoy (&ldquo;D. Portnoy&rdquo;) is, and has, since late 2011 been, the Chairman of the Board and one of its co-CEOs.
He is a citizen of the State of Florida and a resident of Miami. Although the Company has at all relevant times been based in
Oldsmar, Defendant Portnoy has chosen not to live in Oldsmar or adjacent areas, and instead has required the Company to reimburse
him tens of thousands of dollars in expenses for his commutes from Miami. The total cost to the Company of his perquisites and
other benefits for 2012, the last year for which information is disclosed, was $19,218.<SUP>1</SUP> Defendant D. Portnoy is the
brother of Defendant M. Portnoy. He has, since 2011, run on the same slate of directors as defendants M. Portnoy, Berger, Gaines
and Wheeler (collectively with D. Portnoy, the &ldquo;Portnoy Defendants&rdquo;) and has jointly reported share ownership with
them on Schedule 13. He also previously ran on a slate of directors in 2007 with defendants M. Portnoy and Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">16. &nbsp;&nbsp;Defendant Mark L. Portnoy
(&ldquo;M. Portnoy&rdquo;) is, and has, since late 2011 been, a director of the Company and one of its co-CEOs. He is citizen of
the State of Florida, and, on information and belief, resides in the Tampa area. Defendant M. Portnoy has, since 2011, run on the
same slate of directors as defendants D. Portnoy, Berger, Gaines and Wheeler and has jointly reported share ownership with them
on Schedule 13. He also previously ran on a slate of directors in 2007 with defendants D. Portnoy and Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><SUP>1</SUP><FONT STYLE="font-size: 10pt">This
figure is likely understated because it included only perks calculated on the &ldquo;basis of aggregate incremental cost.&rdquo;
The true economic cost of D. Portnoy&rsquo;s perks, including his personal travel expenses, is unknown.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">17.&nbsp;&nbsp;Defendant Anthony Atala (&ldquo;Atala&rdquo;)
is, on information and belief, a resident of the State of North Carolina and a Professor of Urology at Wake Forest University.
Defendant Atala was a director on the Company&rsquo;s Board from late 2012 until late 2013 when he was not re-nominated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">18.&nbsp;&nbsp;Defendant Harold Berger (&ldquo;Berger&rdquo;),
is, and, since late 2011 has been, a director of the Company, the Chair of the Board&rsquo;s Audit Committee and a member of its
Compensation Committee and Governance Committee. He is a citizen of the State of Georgia where he has his own accounting practice.
For at least several years, Defendant Berger has provided accounting services to Defendant M. Portnoy. Defendants have not disclosed
the amount of fees paid for these services. Defendant Berger has, since 2011, run on the same slate of directors as defendants
D. Portnoy, M. Portnoy, Gaines and Wheeler and has jointly reported share ownership with them on Schedule 13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">19.&nbsp;&nbsp;Defendant George Gaines (&ldquo;Gaines&rdquo;)
is, and since late 2011, has been, a director of the Company, the Chair of the Board&rsquo;s Compensation Committee and a member
of the Board&rsquo;s Audit Committee and Governance Committee. He is a citizen of the State of Illinois. Defendant Gaines, purportedly
on behalf of the Company, signed the compensation agreement and amendments thereto for defendants D. Portnoy and M. Portnoy. Defendant
Gaines has, since 2011, run on the same slate of directors as defendants D. Portnoy, M. Portnoy, Berger and Wheeler and has jointly
reported share ownership with them on Schedule 13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">20.&nbsp;&nbsp;Defendant Jonathan H. Wheeler
is, and, since 2011 has been, a director of the Company and Chair of the Board&rsquo;s Governance Committee, which met only once
in 2012, and a member of its Audit Committee and Compensation Committee. Dr. Wheeler is a citizen of the State of California. Defendant
Wheeler, has, since 2011, run on the same slate of directors as defendants D. Portnoy, M. Portnoy, Berger and Gaines and has jointly
reported share ownership with them on Schedule 13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">21.&nbsp;&nbsp;The Individual Defendants
are liable as direct participants in and/or aiders and abettors of the wrongdoing complained of herein, and have ratified all the
intentional, reckless and grossly negligent misconduct complained of herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">22.&nbsp;&nbsp;Each of the Individual Defendants
informed themselves of the unlawful, intentional, reckless, and grossly negligent acts and omissions, which each Individual Defendant
caused and directed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>DEFENDANTS&rsquo; DUTIES AS CRYO CELL
OFFICERS AND DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">23.&nbsp;&nbsp;By reason of their positions
as officers, directors, and/or fiduciaries of Cryo Cell, and because of their ability to control its business and corporate affairs,
the Individual Defendants owed the Company and its shareholders fiduciary duties that included candor, good faith, care, and loyalty,
and were and are required to use their utmost ability to control and manage Cryo Cell in a fair, just, honest, and equitable manner,
so as to benefit all shareholders, not their own personal interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">24.&nbsp;&nbsp;To discharge their common
law fiduciary duties, the officers and directors of Cryo Cell were required to exercise reasonable and prudent supervision over
the management, policies, practices, and controls of the affairs of the Company. By virtue of such duties, they were required to,
among other things: (a) ensure that the Company complied with its legal obligations and requirements, including acting only within
the scope of its legal authority; (b) avoid wasting the Company&rsquo;s assets; and (c) discharge their fiduciary duties, including
loyalty, prudence and candor in disclosures to shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SUBSTANTIVE ALLEGATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in"><B>The Portnoy Defendants&rsquo; Failed 2007 Campaign/Related
Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">25.&nbsp;&nbsp;In 2007, the Portnoys, along
with Defendant Berger, sought election to the Board. After they lost, D. Portnoy challenged the results of the 2007 election, including
the election of director Andrew Filipowski and his nominee, before the Delaware Chancery Court in an action styled in<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><I>Portnoy
v. Cryo-Cell International, Inc.</I>, C.A. No 3142-VCS (the &ldquo;2007 Lawsuit&rdquo;). D. Portnoy commenced the 2007 Lawsuit
by filing a complaint on or about August 3, 2007. He alleged that Mercedes Walton (&ldquo;Walton&rdquo;), the Company&rsquo;s then-CEO,
and other of the Company&rsquo;s directors had breached their fiduciary duties by their conduct during the directorial election
held at the Company&rsquo;s 2007 Annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">26.&nbsp;&nbsp;On January 15, 2008, then
Vice Chancellor Strine, the judge presiding over the 2007 Lawsuit, issued his post-trial findings and rulings. The court first
noted the Portnoys&rsquo; inexperience in public companies or in the stem cell industry. It also found much of the challenged conduct
to be lawful. However, the court found that some of Walton&rsquo;s behavior, in particular her conduct during the Company&rsquo;s
2007 annual meeting, improperly exhibited a lack of candor and breached fiduciary duties she owed. While criticizing Walton&rsquo;s
conduct, the court also criticized the Portnoys&rsquo; litigation conduct, finding that they had improperly made use of the Company&rsquo;s
confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">27.&nbsp;&nbsp;Ultimately, the court ordered
that the directorial election be re-held at a Special Meeting. The Portnoys had also asked to be declared the de facto victors
of the 2007 directorial election, for an award of their costs incurred during their 2007 directorial election campaign and for
their attorneys&rsquo; fees incurred during the 2007 Lawsuit. The court rejected each of these requests, ruling that the Portnoys
were not legally entitled to any of this additional relief, again relying in part on the Portnoys&rsquo; misuse of confidential
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">28.&nbsp;&nbsp;The Portnoys did not seek
election to the Board in 2008, including at the Special Meeting held on March 4, 2008.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">29.&nbsp;&nbsp;At this Special Meeting,
Plaintiff was elected as one of the Company&rsquo;s directors, serving in this position until the summer of 2011 when he was not
re-nominated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">30.&nbsp;&nbsp;In March 2010, defendant
D. Portnoy, still displeased with the Company&rsquo;s then management, contacted Plaintiff asking that Plaintiff either align himself
with the Portnoys or else buy out defendant D. Portnoy&rsquo;s Cryo Cell shares. Plaintiff declined this offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>The Portnoy Defendants Are Elected in 2011</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">31.&nbsp;&nbsp;In the summer of 2011, the
Portnoys again sought election to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">32.&nbsp;&nbsp;In their solicitations to
shareholders during this time period, the Portnoy Defendants noted their 2007 efforts to gain election to the Board:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">By the time the decision in the 2007 Lawsuit was rendered
on January 15, 2008, Mr. [D.] Portnoy had spent so much money&hellip;Accordingly, Mr. Portnoy did not solicit proxies in connection
with the court-ordered special election which occurred on March 4, 2008&hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">33.&nbsp;&nbsp;The Portnoy Defendants also
criticized management&rsquo;s compensation practices. In their view, Cryo Cell historically had a &ldquo;consistent practice of
approving<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>excessive management compensation, including the
granting of a disproportionate number of stock options to management despite its failure to achieve explicitly stated prior objectives.&rdquo;
Thus, the Portnoy Defendants noted that one of platforms of their 2011 directorial campaign was to &ldquo;Reduce executive cash
compensation, and more closely align overall executive compensation to Cryo-Cell&rsquo;s performance.&rdquo; This point was reiterated
throughout the Portnoy Defendants&rsquo; shareholder solicitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">34.&nbsp;&nbsp;On August 8, 2011, the Company
announced that its financial advisors would pursue strategic alternatives to enhance shareholder value, including the sale of the
Company. The Company noted that in the summer of 2011 it had engaged Morgan Joseph TriArtisan LLC as an investment banker and financial
adviser, which had contacted a large number of &ldquo;potential strategic and financial buyers&rdquo; and that it had authorized
&ldquo;negotiations with one or more of these parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">35.&nbsp;&nbsp;On August 12, 2011, the Portnoy
Defendants criticized the Board&rsquo;s handling of the referenced negotiations. They noted that: &ldquo;[w]e believe we are clearly
qualified to evaluate the best strategic alternatives for Cryo-Cell, and will do so with the mutual interests of all Cryo-Cell
stockholders in mind.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">36.&nbsp;&nbsp;At around this time, Defendant
D. Portnoy communicated with Plaintiff about the possibility of pursuing a combined slate of Cryo Cell directors. Plaintiff discussed
this issue with the Portnoys in the hopes of continuing to improve the Company&rsquo;s governance and performance. Discussions
proceeded to the point that he sent the Portnoys a term sheet attempting to memorialize an arrangement whereby Plaintiff and/or
his nominees and the Portnoy Defendants would serve together on the Board. Ultimately, Plaintiff decided that D. Portnoy displayed
a complete lack of candor in his discussions with Plaintiff, making representations without following through. Accordingly, on
or about August 24, 2011, Plaintiff decided that the course that best suited the interest of shareholders was to vote for then-current
management&rsquo;s nominees. Plaintiff did so despite not having a voting agreement with this group and despite not being re-nominated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">37.&nbsp;&nbsp;At the Company&rsquo;s 2011
Annual Meeting, on August 25, 2011, an election of directors was held. The election results were certified on August 30, 2011,
and the Company announced the results of the election in a Form 8-K on August 31, 2011. The Form 8-K disclosed that the Portnoy
Defendants, along with Defendant Atala, were the six director candidates who received the largest number of votes and thus were
elected to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Immediately After the 2011 Election, the Portnoys
Appoint Themselves as Co-CEOs and Immediately Award Themselves Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">38.&nbsp;&nbsp;On September 2, 2011, the
Company, by and through the Individual Defendants, announced in a Form 8-K that as of August 31, 2011, the Board had terminated
former Cryo-Cell CEO Mercedes Walton.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">39.&nbsp;&nbsp;In that same Form 8-K, the
Company announced that the Individual Defendants had appointed Defendants D. Portnoy and M. Portnoy as co-CEOs of the Company.
They further disclosed that the Individual Defendants had granted each of the Portnoys 100,000 stock options of Cryo Cell stock.
According to the press release, &ldquo;[t]he options vest in three tranches, with 33% of the options vesting on the date of grant;
33% vesting on the one-year anniversary of the date of grant; and 33% vesting on the two-year anniversary of the date of grant.&rdquo;
The Form 8-K did not disclose any possibility of accelerated vesting for these option grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">40.&nbsp;&nbsp;On October 17, 2011, Defendants
D. Portnoy and M. Portnoy caused the Company to issue its Form 10-Q for the Third Quarter of 2011. According to the Form 10-Q,
the Company&rsquo;s stock compensation expense for the quarter increased by $280,000 (to $314,000) compared to the same quarter
in 2010, attributable to the stock grants the Individual Defendants gave to the Portnoys. Notably, the grants to the Portnoys were
made despite the fact that the Company reported a net loss of close to $2.4 million for the quarter. Thus, contrary to their prior
representations, the Portnoys immediately awarded themselves substantial stock options without any meaningful achievements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>The Portnoys Improperly Award Themselves Fees and
Costs Associated With Their Failed 2007 Election</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">41. &nbsp;&nbsp;In the same Form 10-Q, the Company
disclosed that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">On August 31, 2011 the Company&rsquo;s Board of Directors
approved the reimbursement by the Company to the Portnoy Group of its costs associated with the litigation resulting from the 2007
Annual Meeting [i.e. the 2007 Lawsuit] and the 2011 Annual Meeting&rsquo;s proxy contest. The total costs reimbursed were approximately
$528,000 and are reflected in marketing, general and administrative expenses in the accompanying consolidated statements of operations
for the three and nine months ended August 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Form 10-Q made no disclosure about any sums the Company
reimbursed any affiliates of the Portnoys.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">42. &nbsp;&nbsp;No reasonable justification
for this reimbursement exists since the judge presiding over the 2007 Lawsuit had already determined that defendant D. Portnoy
was not entitled to attorneys&rsquo; fees in connection with the 2007 Lawsuit. In a later disclosure the Company indicated that
the Individual Defendants may have actually improperly caused the Company to reimburse hundreds of thousands of dollars in additional
fees and costs beyond those included in the $528,000 figure above. According to the Company&rsquo;s Form 10-K for Fiscal 2011:
&ldquo;the Company reimbursed Focus Financial Group approximately $349,506 related to the reimbursement of the Portnoy Group of
its costs associated with the litigation resulting from the 2007 Annual Meeting and the 2011 Annual Meeting&rsquo;s proxy contest.
David Portnoy is the chairman of Focus Financial&hellip;&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Individual Defendants Revoke an Earlier Resolution
to Accelerate Options While Accelerating the Portnoys&rsquo; Options in an Entrenching Manner</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">43.&nbsp;&nbsp;According to the Company&rsquo;s later SEC filings,
on November 23, 2011, the Individual Defendants revoked an earlier August 24, 2011 resolution, that had been put in place by the
predecessor board which accelerated the rate at which stock option grants to directors vested upon a change in control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">44.&nbsp;&nbsp;The Individual Defendants revoked the August
24, 2011 resolution of the predecessor Board despite the fact that the accelerated vesting of stock options and an extended exercise
period are not uncommon in the event of an actual change of control of a company, for example where a company experiences a substantial
overhaul of its board of directors or a substantial change in its capital structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">45.&nbsp;&nbsp;The Individual Defendants caused the Company
to enter into employment agreements with each of the Portnoys as of December 1, 2011. Each of these agreements was signed by Defendant
Gaines on behalf of the Company. Despite having just granted the Portnoys 100,000 options each two months prior, the employment
agreements lavished cash and an additional 200,000 options upon each of the Portnoys, largely without any challenging targets.
Again, this conduct parallels that which the Portnoys challenged just months earlier in their 2011 directorial campaign. The Company&rsquo;s
Form 8-K, filed with the SEC on December 7, 2011, described the employment agreements as follows, noting their options grants,
travel perks, and golden parachutes, among other features:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">The employment agreements provide for annual base salaries
of $225,000 for David Portnoy and $200,000 for Mark Portnoy. In addition to base salary, for the fiscal years ending November 30,
2012 and November 30, 2013, the Executives will be entitled to a performance-based bonus of an amount up to 35%, 65% or 100% of
base salary, depending on whether the stated performance targets are achieved. The agreements each provide a signing bonus in the
form of non-qualified stock options. Accordingly, on December 1, 2011, the Executives were each granted stock options to acquire
200,000 shares of Company stock at $1.72 per share, which was the closing price of the Company's stock on that day. One-third of
the award is vested on the day of grant, one-third becomes vested on the first anniversary of the grant date, and one-third becomes
vested on the second anniversary of the grant date.<B> </B>If specified performance targets are achieved at the &ldquo;stretch&rdquo;
level and if the Executives are still employed by the Company as of November 30, 2013, then each of them will receive a grant of
non-qualified stock options of up to 300,000 shares. Such grants shall be made no later than February 28, 2014 and shall have a
grant price equal to $1.72, which is the closing price of the Company&rsquo;s stock on December 1, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">The agreements also provide for reimbursement for all business
expenses, including the reasonable moving expenses incurred for Mark Portnoy to relocate his primary residence to Tampa, Florida
and reasonable commuting expenses for David Portnoy between his home in Miami, Florida to the Company&rsquo;s headquarters in Tampa,
Florida, including lodging and rental car expenses for when he is working in the Company's offices in Tampa. The Executives&rsquo;
principal place of employment shall be at the Company&rsquo;s headquarters, but David Portnoy may elect in his discretion to work
from his residence in Miami, Florida. The Company shall pay the Executives&rsquo; reasonable legal and financial consulting fees
and costs incurred in negotiating the agreements and shall pay each of them up to $75,000 in legal fees related to any dispute
or question of interpretation regarding the agreements. The Executives will also participate in the employee benefit plans that
the Company generally makes available to Company employees from time to time, including retirement and health plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">Upon the occurrence of an involuntary termination of employment
or a voluntary termination of employment for &ldquo;Good Reason&rdquo; (as defined in the agreements), the agreements provide for
severance pay equal to the greater of one times the Executive&rsquo;s then-current annual base salary or the Executive&rsquo;s
then-current base salary for the remaining term of the agreement, paid in a lump sum. However, if such termination of employment
is in connection with a change in control (as defined in the agreements) that occurs before December 1, 2012, then the agreements
provide for severance pay equal to two times the Executive&rsquo;s then-current base salary and the Company will reimburse the
Executive, on a grossed up basis, for any penalty taxes owed on any excess parachute amounts under Section 280G of the Internal
Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;). In addition, the Company shall provide, at no cost to the Executive,
continued life insurance coverage and nontaxable medical, dental and disability insurance coverage substantially similar to the
coverage maintained by the Company for the Executive prior to such termination for 36 months after the termination. If the termination
of employment is due to disability (as defined in the agreements), the agreements provide for the continuation of the Executive&rsquo;s
base salary for the greater of one year or the remaining term of the agreement. If the termination of employment is due to death,
the agreements provide for payment of the Executive&rsquo;s base salary for one year after his date of death, and the Company will
continue to provide medical and dental coverage for the Executive's family for one year after the Executive&rsquo;s death. The
agreements include a one-year non-competition restriction and a two-year restriction on solicitation of employees or customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">The foregoing description of the employment agreements is
qualified in its entirety by reference to the employment agreements that are attached hereto as Exhibit 10.1 and Exhibit 10.2 of
this Current Report, and are incorporated by reference into this Item 5.02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">46.&nbsp;&nbsp;Though not disclosed in the
text of the Form 8-K, the Portnoys&rsquo; employment agreements purport to allow them to vote even unvested options immediately
in matters brought to a shareholder vote, including directorial elections. Likewise, their employment agreements make the Portnoys&rsquo;
initial stock option grants in September 2011 and their grants in December 2011 subject to acceleration upon a &ldquo;Change of
Control.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">47.&nbsp;&nbsp;The Portnoys&rsquo; employment
agreements define &ldquo;Change of Control&rdquo; broadly to include, among other things, when:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">(d) the Company has received a Nomination Solicitation Notice,
as that term is defined in Article II, Section 10 of the Company's Bylaws, which Nomination Solicitation Notice is determined to
have been filed in a timely manner and in compliance with the Company's Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">48.&nbsp;&nbsp;The
Portnoys&rsquo; December 2011 option grants were to be made pursuant to the Company&rsquo;s 2012 Stock Plan (the &ldquo;2012 Plan&rdquo;).
This plan was first adopted on December 1, 2011 -- the same date as their employment agreement -- without shareholder approval.
It is unsurprising that the Portnoys neither sought not obtained shareholder approval for the initial adoption of the 2012 Plan
given that just months earlier the Portnoy Defendants voiced repeated criticisms of the Company&rsquo;s compensation practices.<SUP>2
</SUP>The Company announced the terms of the 2012 Plan in its Form 8-K filed with the SEC on December 7, 2011, which purported
to authorize the Board to grant up to 1.5 million shares of common stock in equity awards, including stock option awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">49.&nbsp;&nbsp;The 2012 Plan made grants
under it subject to acceleration upon a &ldquo;Change in Control&rdquo;, which was defined, among other ways, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><B>(d) on or before December 1, 2012,
</B>the Company has received a Nomination Solicitation Notice, as that term is defined in Article II, Section 10 of the Company's
Bylaws, which Nomination Solicitation Notice is determined to have been filed in a timely manner and in compliance with the Company&rsquo;s
Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0; text-align: justify">(Emphasis added).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">50.&nbsp;&nbsp;Thus, the Individual Defendants defined &ldquo;Change
of Control&rdquo; in the Portnoys&rsquo; employment agreements very broadly to ensure that any <I>challenge</I> to their control
over the Company triggered acceleration of all options granted to them &ndash; even options granted before they entered into employment
agreements. By contrast, they limited the application of similar provisions in the 2012 Plan through December 1, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>2</SUP> Ultimately, the Company sought
and obtained approval of the 2012 Plan six months later at the Company&rsquo;s 2012 Annual Meeting. Before seeking such approval,
the Individual Defendants increased the 2012 Plan from 1.5 million shares to 2.5 million shares in some unspecified date in May
2012. While the Company first disclosed that the 2012 Plan would be presented for shareholder approval in its Form 8-K filed with
the SEC on May 22, 2012, the amendment enlarging the 2012 Plan to 2.5 million shares was not first disclosed until mentioned in
the Portnoy Defendants&rsquo; preliminary 2012 proxy statement, filed with the SEC on June 8, 2012. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">51.&nbsp;&nbsp;Defining the term &ldquo;change of control&rdquo;
to include the mere nomination of a completing slate of directors with no time limitation (as the Individual Defendants did in
both the Portnoys&rsquo; employment agreements), is unusual and reflects a course of conduct by the Individual Defendants&rsquo;
aimed at entrenching the Portnoys.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">52.&nbsp;&nbsp;Not content with the options they had already
granted, the Portnoys later lowered the performance targets in the employment agreements without consideration to the Company.
On February 17, 2012, the Company filed a Form 8-K with the SEC, which included amendments to the Portnoys&rsquo; employment agreement.
The amendments were dated as of February 13, 2012 and were executed by Defendant Gaines on behalf of the Company. These amendments
purported to &ldquo;clarify&rdquo; the Portnoys&rsquo; employment agreements such that the targets set in those agreements now
applied without regard to the costs of the bonuses and stock option grants themselves (<I>i.e.</I> gross rather than net). This
was a material change &ndash; as will be shown below the compensation costs of the Portnoys&rsquo; employment packages, and especially
the costs of their accelerated stock options grants have been a substantial component of the Company&rsquo;s net losses. Though,
these &ldquo;clarifications&rdquo; amounted to material amendments to the Portnoys&rsquo; employment agreements which were entirely
in the Portnoys&rsquo; favor, and they were not supported by any consideration to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The December 2011 Filipowski Share Purchase</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">53.&nbsp;&nbsp;Several days after the Company filed its December
7, 2011 Form 8-K, the Company filed another Form 8-K, dated December 12, 2011, which first disclosed that on December 1, 2011 (the
same date as the Portnoys&rsquo; employment agreements were executed and the 2012 Plan was adopted) the Individual Defendants had
authorized the Company to <FONT STYLE="color: black">repurchase up to one million (1,000,000) shares of the Company&rsquo;s outstanding
common stock</FONT>. In that same Form 8-K it was disclosed that, on December 7, 2011 the Company repurchased 383,617 shares of
the Company's common stock at $1.80 per share in a privately negotiated transaction, a premium of more than 5% over reported public
transactions in Cryo Cell stock of that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">54.&nbsp;&nbsp;The identities of shareholders from whom the
Company repurchased shares on December 7, 2011 were not disclosed in the Form 8-K. However, former Cryo Cell director and Portnoy
adversary in the 2007 Lawsuit, Andrew Filipowski disclosed on January 17, 2012 that the Company had bought all but 180,650 of the
Filipowski shareholder group&rsquo;s shares at the price of $1.80 per share on December 7, 2011. In his most recent prior ownership
filing of May 24, 2011, Filipowski had disclosed beneficial ownership of approximately 623,000 shares of Cry Cell common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">55.&nbsp;&nbsp;Thus,
at the very same time that the Individual Defendants lavished additional options with entrenching &ldquo;Change of Control&rdquo;
provisions on the Portnoys, the Portnoys used the Company&rsquo;s coffers to largely eliminate one of their major adversaries
as a shareholder, buying him out at a premium. This course of conduct further reflects the Portnoys&rsquo; entrenching intent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">56.&nbsp;&nbsp;The Individual Defendants have continued to allow
for even more expansive repurchases by the Company of Cryo Cell common stock. In a Form 8-K filed with the SEC on June 7, 2012,
the Company disclosed that it had authorized repurchases of up to 3 million of the Company&rsquo;s shares. And, the Portnoy Defendants
caused approximately 300,000 additional shares to be repurchased in the first half of 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The 2012 Directorial Elections</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">57.&nbsp;&nbsp;On May 30, 2012, Plaintiff submitted a list of
nominees to run against the Individual Defendants in the 2012 directorial elections. In the ensuing months, Plaintiff and his nominees,
on the one hand, and the Individual Defendants, on the other, solicited the votes of the Company&rsquo;s shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">58.&nbsp;&nbsp;In the course of soliciting shareholders, the
Portnoy Defendants made a number of material misrepresentations. For example, they falsely represented that Plaintiff had been
voted off the Board in 2011. In fact, Plaintiff had not sought reelection. The Portnoy Defendants also falsely represented that
Plaintiff had sought to amend the Company&rsquo;s bylaws to allow him to remove directors without cause. In fact, Plaintiff had
sought an amendment to allow any shareholders comprising 15% of shares to call a special shareholders&rsquo; meeting. Such a bylaw
would allow the Company&rsquo;s independent shareholders to exercise superior control in determining the fate of management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">59.&nbsp;&nbsp;Defendants&rsquo; misrepresentations were serious
enough that the SEC wrote defendant D. Portnoy a publicly filed letter dated June 28, 2012, that criticized the Portnoy Defendants&rsquo;
above-mentioned misrepresentations. Faced with the SEC&rsquo;s public criticism of their misrepresentations, Defendants were ultimately
forced to admit (albeit in convoluted fashion) their misrepresentations in a Form 8-K, also filed with the SEC on June 28, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">60.&nbsp;&nbsp;Several of the leading independent
proxy advisory firms analyzed the Company&rsquo;s 2012 directorial election. Glass Lewis noted that the Individual Defendants had
propped up the Company&rsquo;s share price by repurchasing 700,000 shares in a six-month period. It also took issue with the Portnoys&rsquo;
appointment of themselves as co-CEOs, calling this move a &ldquo;veiled and substantial overreach of power.&rdquo; It dismissed
the Individual Defendants&rsquo; claims that a co-CEO structure was necessary as &ldquo;preposterous.&rdquo; Glass Lewis further
noted that, despite the Portnoys&rsquo; criticism of prior management for enriching themselves for hitting easily achievable performance
targets, the Portnoys could hit the performance targets set in their employment agreements by merely continuing to repurchase shares
without any improvement in operating performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">61.&nbsp;&nbsp;Glass Lewis also criticized
the Individual Defendants&rsquo; governance of the Company, noting that the Board lacked either an independent Chairman (D. Portnoy
serves in that role) or an independent lead director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">62.&nbsp;&nbsp;It also expressed concern
over the Portnoy Defendants conduct in soliciting shareholder votes, noting the Portnoy Defendants&rsquo; admitted misrepresentations,
as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">63.&nbsp;&nbsp;Glass Lewis also expressed
concern over prolonged material weakness in the Company&rsquo;s internal controls. The Company purportedly discovered a &ldquo;material
weakness in internal control over financial reporting as of November 30, 2011 related to the Company&rsquo;s identification and
application of the <I>appropriate accounting treatment for non-routine transactions and related documentation thereof.</I>&rdquo;
(Emphasis added). In the Company&rsquo;s Q1 2012 10-Q, the Company disclosed: &ldquo;[W]e believe we have remediated the material
weakness described above, however the new controls have not been operating for a long enough period of time to conclude that the
Company&rsquo;s disclosure controls are effective.&rdquo; Only in its Form 10-K for Fiscal 2012 did the Individual Defendants first
disclose a belief that the Company&rsquo;s internal controls were effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">64.&nbsp;&nbsp;Finally, Glass Lewis expressed
concern about the volume of stock options granted by the Company under the 2012 Plan. These concerns have been borne out by recent
events. According to the Company&rsquo;s Form 10-K for Fiscal 2012, filed with the SEC on February 28, 2013, approximately 1 million
total shares have now been issued under the 2012 Plan, with a weighted average exercise price of $1.72 per share -- down significantly
from the preceding year. Moreover, in total all shares issued under all of the Company&rsquo;s equity plans increased by more than
1.2 million between November 30, 2011 and November 30, 2012, indicating total dilution of the Company&rsquo;s equity by approximately
10% in one year, without including the initial stock option grants the Individual Defendants granted the Portnoys in September
2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">65.&nbsp;&nbsp;As the 2012 directorial election
progressed, the Individual Defendants remained desperate to secure shareholder votes at any cost and thus, again, resorted to further
misrepresentations. This time the misrepresentations were even more serious than earlier, as they directly misrepresented the Company&rsquo;s
financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">66.&nbsp;&nbsp;On July 5, 2012, just five
days before the Company&rsquo;s 2012 Annual Meeting, the Portnoy Defendants issued a press release entitled &ldquo;Key Stakeholders
Support Cryo-Cell International Leadership in Proxy Contest.&rdquo; The first paragraphs of the press release read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">OLDSMAR, Fla. (July 5, 2012) &mdash; Individuals who are
in the best position to observe and evaluate the performance of the current Cryo-Cell International [OTCQB symbol: CCEL] Board
and executive management are strongly supporting them as they face a bid for control of the company by a former Board member. The
group assumed leadership in August 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&bull; George Gaines, chairman of the Cryo-Cell Compensation
Committee, fully supports the new leadership. &ldquo;<B>David and Mark Portnoy know exactly what it takes to reverse the company&rsquo;s
downward trend in revenue. Their plan is already showing positive results&hellip;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Emphasis added).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">67.&nbsp;&nbsp;The emphasized statements
by Defendant Gaines (on behalf of all the Portnoy Defendants) above were materially false and misleading. In fact, as disclosed
in the Company&rsquo;s financial results for the second quarter of 2102, which were first disclosed <I>after the election</I>,
on July 16, 2012, the Company&rsquo;s year over year revenues for the second quarter had declined by more than 4% from the second
quarter of 2011, from $4.6 million to $4.4 million. More significantly, the company&rsquo;s profitability for the quarter year
over year had swung from a $177,000 profit to a $3.2 million loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">68.&nbsp;&nbsp;Upon learning of the Portnoy
Defendants&rsquo; representations in the July 5, 2012 press release, though not yet knowing the as yet un-released results of the
Company&rsquo;s second quarter of 2012, Plaintiff&rsquo;s attorneys informed counsel for the Portnoy Defendants that without disclosure
of the Company&rsquo;s most recent financial results, Defendant Gaines&rsquo;s representations in the July 5, 2012 press release
were improperly incomplete. Plaintiff&rsquo;s attorneys demanded that the Company disclose the quarterly results for the second
quarter of 2012 prior to the Company&rsquo;s annual meeting on July 10, 2012, in order to make their statements materially complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">69.&nbsp;&nbsp;In response to this letter,
counsel for the Portnoy Defendants submitted a letter to the SEC on July 6, 2012, arguing that Defendant Gaines&rsquo;s statements
were substantiated by the fact the Company&rsquo;s revenues had increased between the first quarter of 2012 and the second quarter
of 2012; and their assertion that the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">has taken strategic initiatives to increase revenue which,
in the Company&rsquo;s opinion, further supports Mr. Gaines&rsquo; statement and which the Company believes represents the &ldquo;positive
results&rdquo; referenced by Mr. Gaines. Specifically, management has implemented an outside sales force to sell the Company&rsquo;s
products and services. The Company has had no such outside sales force in place since 2008.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">70.&nbsp;&nbsp;These purported justifications of defendant Gaines&rsquo;s
statement actually compound the Portnoy Defendants&rsquo; misrepresentations. It is materially misleading to compare quarter to
quarter results within the same year, as most businesses experience some degree of seasonal fluctuation, which does not allow for
a meaningful performance comparison between quarters. In fact, the appropriate comparison and the one utilized by the Company in
its SEC filings (and all other companies) is to compare performance in a given quarter of one year to the Company&rsquo;s performance
in the same quarter in the preceding year. Since, by admission in their correspondence to the SEC, the Portnoy Defendants knew
that year over year second quarter revenues had declined to $4.4 million (from $4.6 million in the second quarter of 2011), Defendant
Gaines&rsquo;s representations were materially misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">71.&nbsp;&nbsp;It was further materially
misleading for the Portnoy Defendants to claim to the SEC that the creation of an outside sales force justified Defendant Gaines&rsquo;s
statement that the Company was experiencing &ldquo;positive results.&rdquo; In fact, the costs of this sales force were a direct
component of materially decreased net income. As the Company noted in its Form 10-Q filed with the SEC on July 16, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">The decrease in net income for the six months ended May
31, 2012 principally resulted from &hellip;.. a 40% increase in selling, general and administrative expenses, due mainly to an
increase in stock option compensation and <B>the increase in sales and marketing initiatives including the implementation of a
national sales force.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Emphasis added).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">72.&nbsp;&nbsp;Moreover, fundamentally,
as detailed in the next section below, the creation of a national sales force was, in reality, self-dealing by the Portnoys in
lavishing sums on their friend and convicted criminal David Wayne Fish (&ldquo;Fish&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">73.&nbsp;&nbsp;Ultimately, having deceived
both shareholders and the SEC, the Individual Defendants received the most votes at the Company&rsquo;s 2012 Annual Meeting, held
at the Company&rsquo;s headquarters on July 10, 2012. Thus, the Individual Defendants were ultimately victorious in the Company&rsquo;s
directorial elections. The 2012 Plan was also approved, albeit by a smaller margin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">74.&nbsp;&nbsp;Less than one week after
the 2012 Annual Meeting, on July 16, 2012, the Company announced its financial results for the second quarter of 2012. The Company
disclosed that the decrease in net income for the three months ended May 31, 2012, referenced above, was principally due to a 59%
increase in selling, general and administrative expenses, as further detailed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>The Portnoys Select Their Cronies for
Key Positions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">75.&nbsp;&nbsp;As mentioned above, one of
the major costs to the Company was the creation of a national sales force. For this task, the Individual Defendants delegated authority
to their long time friend Fish. On information and belief, M. Portnoy has been friends with Fish for many years and knows him originally
from M. Portnoy&rsquo;s involvement with the National Basketball Association According to the Company, Fish was engaged as an independent
consultant with the &ldquo;primary purpose of assisting the Company to establish and grow an outside sales force.&rdquo; Though
the precise date Fish was engaged is unknown to Plaintiff, according to the Company&rsquo;s counsel he was associated with the
Company through October 17, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">76.&nbsp;&nbsp;Fish was formerly associated
with Premier Medical Systems Inc. (&ldquo;PMSI&rdquo;) and was convicted in 2010 for engineering a massive workers compensation
fraud and kickback scheme. The California Department of Insurance, the California Franchise Tax Board and the District Attorney
for Los Angeles all charged him with insurance fraud and tax evasion. In a negotiated resolution, Fish was convicted on February
19, 2010 and was sentenced to: three years probation; payment of $390,000 to the California Franchise Tax Board in regard to the
tax evasion charges; payment of $750,000 to the California Department of Insurance; a fine; and agreement to dismiss with prejudice
more than $60 million in liens and bills created by PMSI that were pending before the California Workers&rsquo; Compensation Appeals
Board. In connection with the resolution of claims against Fish, California Insurance Commissioner Steve Poizner noted that: &ldquo;Getting
kickbacks for referring medical payments is illegal&hellip;we were able to prevent $60 million in fraudulent and unnecessary claims
in being made.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">77.&nbsp;&nbsp;During the course of his
association with the Company, it has been alleged that Fish continued to engage in inappropriate behavior. Specifically, in the
action styled <I>Gardinier, et. al. v. Cryocell International, Inc. and David Fish</I>, 37-2012-00084296-CU-WT-CTL filed in the
Superior Court of the State of California for the County of San Diego, the plaintiffs allege that from January to May 2012 Fish
continually sexually harassed them. The Defendants settled the action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">78.&nbsp;&nbsp;Plaintiff is informed and
believes that, while with Cryo Cell, Fish personally selected, hired and managed tens of outside sales persons. While ostensibly
based in California, Fish had business card tying him to Oldsmar, Florida, where the Company is headquartered. He was also heavily
involved in leading and participating in sales calls. However, Cryo Cell personnel understood that he was not and could not be
designated as a company officer given his criminal record.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">79.&nbsp;&nbsp;The Portnoys also caused
the Company to hire Belinc who former employees describe as M. Portnoy&rsquo;s on-again, off-again girlfriend, as an event coordinator.
Because of the nature of her relationship with M. Portnoy, Belinc would thus work intermittently and was not a reliable worker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">80. &nbsp;&nbsp;Likewise, in and about November
2011, less than two months after being appointed as co-CEO, D. Portnoy caused the Company to hire Mikulinsky. Mikulinsky was appointed
as CIO shortly thereafter. He is friendly with D. Portnoy, having previously worked for him at PC and uTIPu for several years.
While titled as CIO, D. Portnoy treats Mikulinsky as a de facto COO, allowing him extensive control over the Company&rsquo;s operations,
including its sales and marketing organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">81.&nbsp;&nbsp;Finally, in late 2011 the
Portnoy Defendants caused the Company to engage PC for consulting services, paying PC approximately $7,000 for such services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>The Aftermath</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">82.&nbsp;&nbsp;Since the Portnoys commenced
their campaign of rampant self-dealing and entrenchment in late 2011, the Company&rsquo;s share price has languished and its profitability
remains decimated. According to the Company&rsquo;s Form 10-K for Fiscal 2012, selling, general and administrative expenses increased
by $2 million (or 14%) in 2012 compared to 2011, largely due to $2.3 million in sales and marketing costs and $996,000 stock option
expenses (much of this latter figure related to acceleration of the Portnoys&rsquo; own options). &nbsp;Notably, these increases
have occurred despite the Company having saved $1.1 million in legal fees and annual meeting expenses; although part of the reason
for such a substantial decline in legal fees is the fact the this amount included the Portnoys&rsquo; payment to themselves in
2011 of fees and costs to which they were not legally entitled in connection with the 2007 Lawsuit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">83.&nbsp;&nbsp;In July 2013 the Portnoy
Defendants were re-elected to the Board in an uncontested election. Despite the absence of competing candidates, the Portnoys received
the votes of fewer than half of the total shares outstanding. An even smaller percentage of shareholders approved their compensation
package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify; text-indent: 0.5in"><B>Derivative and demand-futility allegations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">84.&nbsp;&nbsp;Plaintiff brings this action
derivatively on behalf of Cryo Cell to redress injuries suffered, and yet to be suffered, by the Company as a direct and proximate
result of the breaches of fiduciary duty and other wrongdoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify; text-indent: 0.5in">85.&nbsp;&nbsp;Plaintiff Choi has,
at all relevant times, owned approximately 20% of the Company&rsquo;s common stock. Thus, Plaintiff has been an owner of substantial
amounts of Cryo Cell common stock and one of the Company&rsquo;s largest shareholders at the time of all of the events in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify; text-indent: 0.5in">86.&nbsp;&nbsp;Plaintiff will adequately
and fairly represent the interests of the Company and its shareholders in enforcing and prosecuting Cryo Cell&rsquo;s rights. This
action is not a collusive one to confer jurisdiction on a court that it would not otherwise have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify; text-indent: 0.5in">87.&nbsp;&nbsp;At the time this action
was commenced, the Board consisted of five directors, comprising all of the Portnoy Defendants. A pre-suit demand to pursue legal
action would be and is futile on each member of the Company&rsquo;s Board (i.e. each of the Portnoy Defendants) because each of
them played a central role in the breaches of fiduciary duty, including entrenchment and nepotism alleged herein, and each of them
faces a substantial likelihood of personal liability as a result of their actions and conscious failures to act. The misconduct
complained of herein was not, and could not have been, an exercise of good-faith business judgment. Indeed, when Plaintiff made
informal efforts at reforming Cryo Cell&rsquo;s corporate governance, and when he made a demand to inspect certain books and records,
he was rebuffed with claims that he was somehow pursuing an improper purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify; text-indent: 0.5in">88.&nbsp;&nbsp;Each of the Portnoy
Defendants is incapable of independently and disinterestedly considering a demand to commence and vigorously prosecute this action
against themselves and their co-Defendants. In fact, this would require them to pursue litigation against themselves, as this action
arises out of the Portnoys&rsquo; self-dealing, and in part agreements that Defendant Gaines was a signatory to. In fact, on April
3, 2013, counsel for Plaintiff sent a Request for Inspection of Books and Records demand to the Company to investigate the wrongdoing
alleged herein. Counsel for the Company responded on April 15, 2013, and refused to provide any of the requested information. Despite
the Board&rsquo;s knowledge of alleged wrongdoing, it has refused to take any corrective action and instead, has stonewalled Plaintiff&rsquo;s
attempts to investigate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">89.&nbsp;&nbsp;The Portnoy Defendants have
a history of close business and personal ties. For example, Defendants D. Portnoy and M. Portnoy are brothers. The Portnoy brothers
have extensive dealings together that include serving on the board of PC. They have also affiliated twice in forming a group to
launch a proxy contest against Cryo Cell&rsquo;s incumbent board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">90.&nbsp;&nbsp;Defendant Berger has maintained
close business and personal ties to the Portnoy brothers for many years. Since at least 2007, Berger has maintained a business
relationship with M. Portnoy, providing him with accounting services for compensation. Moreover, Defendant M. Portnoy and Defendant
Berger attended the University of North Carolina, Chapel Hill together for three years while taking courses in related departments
(economics and business).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">91.&nbsp;&nbsp;A number of Defendant Berger&rsquo;s
business dealings with M. Portnoy have involved D. Portnoy as well. As of 2011, Defendant Berger was a shareholder in PC. PC, in
turn, was and is a shareholder of record of Cryo Cell stock. At that same time, D. Portnoy was Chairman of the Board and M. Portnoy
was a Director for PC. Defendant Berger also ran on a proxy slate with both Portnoys, seeking election as the Company&rsquo;s directors
in 2007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">92.&nbsp;&nbsp;Likewise, Defendant Gaines
has been a part of the Portnoys&rsquo; shareholder group since at least 2007 and has been associated with the Portnoys&rsquo; efforts
regarding the Company since that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify; text-indent: 0.5in">93.&nbsp;&nbsp;The pattern and practice
of the Portnoy Defendants&rsquo; breaches of their fiduciary duties to the Company and its shareholders subjects, and will persist
in subjecting Cryo Cell to harm because the adverse consequences of the injurious effects are ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COUNT I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Breach of Fiduciary Duty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(against all Individual Defendants)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">94.&nbsp;&nbsp;Plaintiff incorporates by
reference the allegations contained in each preceding paragraph as if fully set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">95.&nbsp;&nbsp;As alleged in detail herein,
each of the Individual Defendants had fiduciary duties to <FONT STYLE="color: black">exercise their directorial powers in good
faith and with a view to the interests of the corporation</FONT>. This includes behaving in a manner calculated to benefit the
Company and refraining from unduly benefiting themselves and other Individual Defendants at the expense of the Company and its
shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">96.&nbsp;&nbsp;In breach of their fiduciary
duties of loyalty, good faith, candor, and care, the Individual Defendants agreed to and did participate with and/or aided and
abetted one another in a deliberate course of action designed to divert corporate assets to themselves and/or other insiders in
a manner to benefit the Portnoy Defendants and their friends and to ensure their entrenchment with Cryo Cell. The Individual <FONT STYLE="color: black">Defendants&rsquo;
determination of the adequacy of consideration for the subject transactions was a mere pretext to furthering their entrenchment.
Their</FONT> misconduct was not, and could not have been, an exercise of good faith business judgment. Rather, it was intended
to, and did, unduly benefit themselves at the expense of the Company and was made without any reasonable efforts to ensure the
Company&rsquo;s interests were protected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">97.&nbsp;&nbsp;As a result the Company has
sustained damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COUNT II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Abuse of Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(against all Individual Defendants)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">98.&nbsp;&nbsp;Plaintiff incorporates by
reference the allegations contained in each preceding paragraph as if fully set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">99.&nbsp;&nbsp;The Individual Defendants
employed the alleged systematic misconduct for the purpose of maintaining and entrenching themselves in their positions of power,
prestige and profit at, and control over Cryo Cell, and to continue to receive the substantial benefits, salaries and emoluments
associated with their positions at Cryo Cell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">100.&nbsp;&nbsp;The Individual Defendants&rsquo;
conduct constituted an abuse of their ability to control and influence Cryo Cell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">101.&nbsp;&nbsp;As a direct and proximate
result, the Company has sustained damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COUNT III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Corporate Waste</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(against all Individual Defendants)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">102.&nbsp;&nbsp;Plaintiff incorporates by
reference each allegation contained in each preceding paragraph as if fully set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">103.&nbsp;&nbsp;By failing to properly consider
the interests of the Company and its shareholders, by failing to conduct proper supervision, and by giving away many hundreds of
thousands of dollars to the Individual Defendants and those beholden to them, the Individual Defendants have caused Cryo Cell to
waste valuable corporate assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">104.&nbsp;&nbsp;As a direct and proximate
result, the Company has sustained damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COUNT IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Unjust Enrichment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(against all Individual
Defendants)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">105.&nbsp;&nbsp;Plaintiff
incorporates by reference and realleges each and every allegation set forth above, as though fully set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">106.&nbsp;&nbsp;By
their wrongful acts and omissions, the Individual Defendants were unjustly enriched at the expense of and to the detriment of Cryo
Cell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">107.&nbsp;&nbsp;Plaintiff,
as a shareholders and representative of Cryo Cell, seeks restitution from these Individual Defendants, and each of them, and seeks
an order of this Court disgorging all profits, benefits and other compensation obtained by these Individual Defendants, and each
of them, from their wrongful conduct and fiduciary breaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PRAYER FOR RELIEF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Plaintiff, on behalf of Cryo Cell, requests
relief as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">A.&nbsp;&nbsp;For rescission of the transactions
at issue herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">B.&nbsp;&nbsp;For damages against Individual
Defendants in an amount to be proven at trial;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">C.&nbsp;&nbsp;For removal of each Individual
Defendant found to have breached a fiduciary duty to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">D.&nbsp;&nbsp;For return of all compensation
paid by the Company to each Individual Defendant found to have breached a fiduciary duty to the Company to the maximum extent permitted
by law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in; text-align: justify">E.&nbsp;&nbsp;For attorneys&rsquo;
fees to the extent permissible;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">F.&nbsp;&nbsp;For costs of suit incurred
herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">G.&nbsp;&nbsp;For pre-judgment and post-judgment
interest to the extent permissible;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">H.&nbsp;&nbsp;For other or further relief
as the Court may deem just, equitable, or proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>JURY DEMAND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Plaintiff hereby demands a trial by jury for all causes
and issues so triable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; padding-right: 0; padding-left: 0; text-align: justify">Dated: November 13, 2013</TD>
    <TD STYLE="width: 15%; padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 49%; padding-right: 0; padding-left: 0; text-align: justify">Respectfully submitted,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in; border-bottom: Black 1pt solid">/s Peter
    B. King</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">Peter B. King (FBN No. 0057800)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">pking@wiandlaw.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">ncook@wiandlaw.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">Jared J. Perez (FBN No. 0085192)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">jperez@wiandlaw.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">mmadison@wiandlaw.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">WIAND GUERRA KING P.L.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">5505 W. Gray Street</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">Tampa, Florida 33609</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-justify: inter-ideograph; text-indent: 0in">Telephone: (813) 347-5100</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">Facsimile: (813) 347-5151</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><I>Attorneys for Plaintiff Ki Yong Choi on</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><I>Behalf of Cryo Cell International, Inc.</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0; padding-left: 0; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avi Wagner (pro hac vice pending)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE WAGNER FIRM</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1925 Century Park East, Suite 2100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Los Angeles, CA 90067</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone: (310) 491-7949</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fax: (310) 694-3967</P></TD>
    <TD STYLE="width: 50%; padding-right: 0; padding-left: 0; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Peter A. Binkow (pro hac vice pending)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Louis Boyarsky (pro hac vice pending)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GLANCY BINKOW &amp; GOLDBERG LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1925 Century Park East, Suite 2100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Los Angeles, CA 90067</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone: (310) 201-9150</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fax: (310) 201-9160</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>VERIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">I, Ki Yong Choi, being duly sworn, do hereby
state as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">1.&nbsp;&nbsp;My name is Ki Yong Choi and
I submit this verification in connection with the filing of a Verified Derivative Complaint (the &ldquo;Complaint&rdquo;) in the
above-captioned action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">2.&nbsp;&nbsp;I currently hold units of
Cryo-Cell International Inc. and have held such shares continuously throughout the wrongs alleged in the Complaint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">3. &nbsp;&nbsp;I have reviewed and authorized
the filing of the Complaint against the defendants in this action. I am familiar with the allegations of the Complaint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">4.&nbsp;&nbsp;I verify that I have reviewed
the foregoing Complaint and that the allegations as to me and my own actions are true and correct and all other allegations upon
information and belief are true and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">5.&nbsp;&nbsp;Neither I, nor anyone else
affiliated with me, have received, been promised or offered, and will not accept any form of compensation, directly or indirectly,
for prosecuting or serving as a representative party in this action except for (i) fees, costs or other payments as the Court expressly
approves to be paid to me or on my behalf; or (ii) reimbursement, paid by my attorneys, of actual and reasonable out-of-pocket
expenses incurred by me directly in connection with prosecution of this action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">I make this Verification under penalty of
perjury that the foregoing is true and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Executed this 12th day of November, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in; text-align: justify">&#9;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%; padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 38%; padding-right: 0; padding-left: 0; text-align: justify; border-bottom: Black 1pt solid">/s/ Ki Yong Choi</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">KI YONG CHOI</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>v360687_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 99.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JOINT FILING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We, the signatories of the statement to which this Joint Filing
Agreement is attached, hereby agree that such statement is filed, and any amendments thereto filed by any and all of us will be
filed, on behalf of each of us and that this Agreement be included as an exhibit to such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: November 14, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Ki Yong Choi</TD>
    <TD STYLE="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Ki Yong Choi</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Ki Yong Choi and Laura Choi, as Trustees UAD 7/27/01</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>FBO Choi Family Living Trust</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Ki Yong Choi, Trustee</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Ki Yong Choi, Trustee</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Laura H. Choi</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Laura H. Choi, Trustee</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
